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Sequence-specific double-stranded small interfering RNAs (siRNAs) may effectively 
silence gene expression via a mechanism called RNA interference (RNAi). The focus 
of this study was mainly identification of active siRNA sequences against the HER2 
gene. Three anti-HER2 siRNAs that followed published algorithms were designed, 
cloned and then tested in the breast cancer cell line SKBR3. The silencing effects 
were mostly weak and contradictious when investigated by flow cytometry, western 
and northern techniques. The results suggested that other factors than siRNA 
sequence, such as target mRNA secondary structure and cell conditions, might have 
influenced siRNA activity, and that these are important to take into consideration 
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Fig. Figure  
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1. Introduction 
1.1 The molecular nature of cancer 
Cancer includes loss of control of a number of processes; above all, it involves the 
uncontrolled multiplication of cells. The disease is mainly the result of the normal 
process which control cell division being faulty. Cancer always involves multiple 
genetic changes, and there are many different cancers with different specific 
molecular causes (Elliott 2001).  
Oncogenic changes (those leading to the development of cancer) can be divided into 
two broad types. One type involves genetic changes that contribute to cancer 
development due to the loss of functional genes that protect cells against uncontrolled 
cell division. These genes are often called tumor suppression genes. The other type of 
oncogenic changes is due to acquirement or development oncogenes, which give 
abnormal control signals leading to uncontrolled cell division. Oncogenes may be 
acquired through viral infection or by a mutation that changes a normal gene 
(protooncogene) into an oncogene (Elliott 2001).  
Synthesis of DNA in eukaryotes happens in a separate phase (the S phase / synthesis 
phase) discrete from the phase involving cell division (the M phase / mitosis phase). 
The whole cell cycle involves mitosis followed by a gap phase (G1), followed by 
DNA synthesis and another gap phase (G2), before the cell divides again. In the gap 
phases the cell nether synthesises DNA nor divides. The cell cycle in eukaryotes is 
strictly controlled: For the cell to enter the S phase from the G1 phase, it has to receive 
signals through cytokines or growth factor molecules. If the signal is not received, the 
cell enters the quiescent G0 phase until a signal arrives. Mutations that alter the cell 
cycle control and increases cell division, can contribute to cancer (Elliott 2001).   
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1.2 Tyrosine kinase-associated receptors 
Cytokines and growth factor molecules are proteins or polypeptides secreted by many 
cell types, and they are typical of whatever tissue they belong to. Most are paracrine 
in action, and act on local cells, while some are autocrine and influence only the 
secretor cell itself. The signal from growth factors or cytokines is mediated through 
receptors on the membrane of the cells, of which one type is Tyrosine kinase-
associated receptors (Trk receptors). Trk receptors have one external domain to which 
the signal molecule binds non-covalently, a transmembrane domain, and a 
cytoplasmic domain, and they form dimers when signal molecules are bound to the 
external domain (Fig.1).  
 
Figure 1: Trk receptor and signal transduction. The extracellular signal is 
transducted from the signal molecule through receptor and cytoplasmic 
proteins, to the nucleus. 
The dimerisation of a Trk receptor is followed by autophosphorylation of tyrosine 
groups in its cytoplasmic domains. The process is ATP dependent, as the phosphate 
group comes from this molecule. The cytoplasmic domain of the receptor then binds 
to a protein complex. This complex binds to the membrane bound protein Ras (first 
found in Rat sarcoma), which activates a protein kinase cascade (the Ras pathway), 
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which convey the signal to the nucleus, and eventually activates transcription factors 
promoting cell proliferation. The Ras pathway is an ancient, major signalling 
pathway, and any mutation that erroneously activates the pathway would contribute 
to cancer (Elliott 2001). 
1.3 Human epidermal growt factor receptor 2 
The Human epidermal growth factor receptor family (HER family) comprises four 
homologous Trk receptors, namely HER1, HER2, HER3 and HER4. The HER 1 to 4 
genes are also known as erbB 1 to 4. Various lines of evidence have linked the HER 
family to regulation of normal human breast growth and development (DiAugustine 
et al. 1997). Moreover, the HER family has become one of the best characterized 
systems in breast cancer (Cooke 2000). The HER2 gene (also known as neu) has 
growth-stimulating activity and is located on the long arm of chromosome 17 
(Coussens et al. 1985). Normal cells contain two copies of the HER2 gene, which 
encodes a receptor of 1255 amino acids (Akiyama et al. 1986). The receptor is 
expressed in many types of tissue, including nervous system, bone, muscle, skin, 
lungs and intestinal epitelum, and expression levels of HER2 are higher in foetal 
tissues than in adult tissues (Press et al. 1990; Cooke 2000). Depending on the cell 
type involved and the type of ligand binding to the receptor, HER2 activation can 
inhibit or stimulate cell proliferation (Peles et al. 1992). This probably correlates with 
the levels of various other HER receptors expressed by the particular cell type, as 
HER2 forms heterodimers with these. The HER2 homodimer has a particularly high 
ligand-binding potency and appears to have greater activity than other HER 
heterodimers or homodimers (Sliwkowski et al. 1994). When there are more than five 
copies of the HER2 gene, it is considered amplified, and studies have linked gene 
amplification and HER2 overexpression to cancer development, even though this is 
not an initiating event (Di Fiore et al. 1987a; Di Fiore et al. 1987b). The HER2 gene 
is amplified in 25-30% of all cases of breast cancer (Slamon et al. 1989). 
Amplification results in expression on the cell surface at levels 10- to 100-fold 
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greater than normal, and this event occurs relatively early in the development of 
cancer (Cooke 2000). Since amplification of HER2 contributes to breast cancer by 
increasing growth potential and makes it more difficult to treat by rendering cells 
resistant to apoptic factors (Yarden 2001), silencing the HER2 gene might be helpful 
in cancer therapy. One technique of gene silencing involves small interfering RNAs 
(siRNAs), and this will be discussed in the following sections. 
1.4 The discovery of RNA interference 
The first paper describing RNA silencing may have been published as long ago as 
1928 (Baulcombe 2004). This paper described tobacco plants in which only the 
initially infected leaves were necrotic and diseased owing to tobacco ringspot virus. 
The upper leaves had somehow become immune to the virus and consequently were 
asymptotic and resistant to secondary infection (Baulcombe 2004). Strange gene 
silencing effects were again brought to attention in the early 90ies, during 
experiments connected with changes in pigmentation in the petunia. Genes designed 
to deepen flower colour were introduced, but surprisingly the colour intensity became 
weaker (Napoli et al. 1990). This phenomena was termed co-suppression. A similar 
phenomena in Nicotiana tabacum was termed Post-Transcriptional Gene Silencing 
(PTGS) (de Carvalho et al. 1992), and this was shown to be a nucleotide sequence-
specific defence mechanism that targeted both cellular and viral mRNAs (Hamilton et 
al. 1999; Vance et al. 2001). In fungi, a gene silencing phenomena named quelling 
was discovered (Romano et al. 1992).  
In 1998 Fire et al. made a ground breaking discovery by showing that double-
stranded RNAs (dsRNA) could effectively interfere with a corresponding gene when 
introduced into Caenorhabditis elegans. When wild type animals were fed with 
bacteria expressing a dsRNA segment from the unc-22 gene, 85% of them exhibited a 
weak but distinct twitching phenotype, characteristic of partial loss of function for the 
unc-22 gene (Timmons et al. 1998). The effect was termed RNA interference or 
RNAi. It was later observed that silenced genes tended to have short RNAs 
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associated with them, and that dsRNA was prosessed into 21-23-nt RNA fragments 
when introduced into Drosophila cells (Hamilton et al. 1999; Zamore et al. 2000). 
This led to the finding that RNA interference is mediated by 21- and 22-nt RNAs, 
demonstrated with synthetic RNAs by the group of Thomas Tuschl (Elbashir et al. 
2001a). It was found that the 21- and 22-nt RNAs (siRNAs), act as the guide RNAs 
for sequence-spesific mRNA degradation, when base paired with 3’ overhanging 
ends (Elbashir et al. 2001a). Target mRNA cleavage sites relative to the siRNAs were 
also defined (Elbashir et al. 2001a). RNAi of specific genes in mammals was 
previously limited by virus detection systems and interferon responses when dsRNA 
was introduced, but siRNAs bypass these systems (Elbashir et al. 2001b). RNAi 
either by exogenously or endogenously expressed siRNA was now recognised as a 
revolutionary new tool for analysis of gene function and gene therapy.  
Later, molecular level comparison of various silencing phenomena (including PTGS, 
co-suppression, quelling and RNAi) in various species, revealed them to share a 
common underlying mechanism that reflects an ancient origin in a common ancestor 
(Mello et al. 2004). The mechanism has become known as the RNAi machinery, and 
the various silencing phenomena mediated by this machinery are now known 
collectively as RNAi.   
1.5 The mechanism of interference by siRNAs 
The present model of RNAi by siRNA is built on several observations (Timmons et 
al. 1998; Fire 1999; Hamilton et al. 1999; Tuschl et al. 1999; Hammond et al. 2000; 
Zamore et al. 2000; Ambros 2001; Bernstein et al. 2001; Hammond et al. 2001; 
Nykanen et al. 2001; Elbashir et al. 2001a; Hutvagner et al. 2002; Zhang et al. 2002; 
Martinez et al. 2002i). SiRNAs are 21-23 nt dsRNA duplexes with 2-3 nt 3’ 
overhangs and 5’-phosphate and 3’-hydroxyl groups (Fig.2a). They are produced 
when the enzyme Dicer cleaves long dsRNA, as shown in Fig.2b. The siRNAs are 
incorporated in a multiprotein RNA induced silencing complex (RISC). There is 
strict requirement for the siRNA to be 5’ phosphorylated to enter into RISC, and 
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siRNA that lack a 5’ phosphate are rapidly phosphorylated by an endogenous kinase. 
The duplex siRNA is unwound by a helicase in RISC, leaving the antisense strand to 
guide RISC to its homologous target mRNA for endonucleolytic cleavage 
(Dykxhoorn et al. 2003).  
 
Figure 2: RNA interference by siRNA. 2a) An siRNA. 2b) The siRNA 
pathway: Long dsRNA is cleaved by Dicer into siRNAs, in an ATP-
dependent reaction. These siRNAs are then incorporated into RISC. 
Unwinding of the siRNA duplex also requires ATP. The antisense strand of 
the siRNA guides RISC to an mRNA with a complementary sequence, 
resulting in endonucleolytic cleavage of the target mRNA. 2c) Synthetic 
siRNA. (Modified from (Dykxhoorn et al. 2003).) 
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The target mRNA is cleaved at a single site in the centre of the duplex region 
between the guide siRNA and the target mRNA, 10 nucleotides from the 5’ end of 
the siRNA antisense strand. Cleaved mRNA is further degraded by cellular 
ribonucleases (Dykxhoorn et al. 2003). The siRNA strand that binds the target 
mRNA can become extended by RNA-dependent RNA polymerase (RdRP), 
producing more dsRNA that then provide further substrates for Dicer (Sijen et al. 
2001). Such amplification of silencing occurs in various stages of the RNAi pathway 
and has been documented in plants and worms (Sioud 2005a). Synthetic siRNAs 
(Fig.2c) are RNAs engineered to look like the products of Dicer, and are shown to 
induce sequence-specific gene silencing in human cells without initiating non-
specific gene silencing pathways (Elbashir et al. 2001b). Notably, recent experiments 
demonstrated that a certain group of synthetic siRNAs can activate innate immunity, 
leading to cytokine and interferon production (Sioud 2005b). 
1.6 A potential biological role of siRNAs 
RNAi has been observed in a vide range of species, including plants, fungi, 
nematodes, protoza, insects and vertebrates (Fire 1999; Hamilton et al. 1999; Ketting 
et al. 1999; Tabara et al. 1999; Yang et al. 2000; Zamore et al. 2000; Hutvagner et al. 
2002; Lindenbach et al. 2002; Salo et al. 2002; Urwin et al. 2002). This implies that 
RNAi is an evolutionary highly conserved mechanism of an early origin. In addition 
to siRNAs, RNAi can be mediated by microRNAs (miRNA). This class of natural 
hairpin dsRNAs, was shown to be processed by Dicer (Hutvagner et al. 2001) and to 
function together with RDE-1 gene homologues (Grishok et al. 2001), thereby 
linking RNAi to the natural developmental gene regulatory mechanism. Differing 
from siRNAs, there are commonly sequence mismatches between miRNAs their 
target mRNAs, leading to translational arrest, and not degradation of the mRNA 
(Ambros 2001; Ambros et al. 2003; Mello et al. 2004). In contrast to miRNAs, 
siRNAs have not been proven to have any regulatory role.  
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Since RNAi mechanisms involving siRNAs have been shown to suppress 
transoposons and retroviruses (Angell et al. 1997; Baulcombe 1999; Ketting et al. 
1999; Tabara et al. 1999; Mette et al. 2000; Vance et al. 2001; Lindenbach et al. 
2002), it has been suggested that silencing through siRNAs may be part of a billion 
years old immune system (Bagasra et al. 1997). A typical symptom of retro-virus 
infection is dsRNA in the cytoplasm, and since the siRNA effect involves dsRNA, it 
may be a cellular defence mechanism utilizing viral RNA (Bagasra et al. 2004). Also, 
some viruses have proteins to specifically knock out RNAi in several eukaryotes 
(Vance et al. 2001; Li et al. 2002). This could indicate co-evolution between cell 
defence mechanisms and viral counter-defence. This so-called hypothesis of the 
molecular immune system might help explain, at least partially, the existence of DNA 
which seemingly is not transcribed (“junk” DNA): The extensive retention of 
retroviral sequences in eukaryotic life forms suggests a beneficial function for these 
sequences in the course of evolution, and some speculate that the massive 
accumulation of genomic retroelements may account for its defensive function 
against newly-arriving retroviruses (Bagasra et al. 2004). By utilizing gene sequences 
accommodated in the past, the host might preserve its genome from further 
encroachment by potentially hostile new retroviruses, via RNAi (Bagasra et al. 
2004). 
1.7 Delivery and rational design of siRNAs 
After the demonstration of RNAi in mammalian cells by chemical synthesis (Elbashir 
et al. 2001b), there have been developed  several techniques of siRNA delivery, 
including in vitro trancription (Donze et al. 2002; Leirdal et al. 2002) and vector 
based delivery (Miyagishi et al. 2002; Brummelkamp et al. 2002a). In this study, 
plasmid vectors encoding short hairpin RNAs (shRNAs) were delivered to cell 
nucleuses via Lipofectamine; a commercially available lipid-based transfection agent. 
In the present method, the siRNA sense and antisense strands are expressed as a 
single transcript separated by a short loop sequence (see Fig.3). The antisense 
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sequence is followed by at least five thymidines; a transcriptional termination signal 
for RNA polymerase III. Following transcription, the transcript is expected to forms a 
hairpin structure that is transported to the cytoplasm for processing by Dicer into a 
functional siRNA (Paddison et al. 2002; Paul et al. 2002; Brummelkamp et al. 
2002a). 
 
Figure 3: Processing of hairpin RNA. The DNA is transcribed to shRNA with 
sense and antisense strands that associate in cis. In the cytoplasm, Dicer 
processes shRNA to functional siRNA. (Modified from (Dykxhoorn et al. 
2003).)  
Synthetic siRNA duplexes can be delivered in vivo via either lipids or the 
electrophoration method. The same apply for short hairpin RNAs (shRNAs) 
expressed from integrated pol III promoter in plasmid vectors (Sioud 2005a). SiRNA 
conjugated with cell-penetrating peptides, cholesterol or folic acid, can be added 
directly to the cells, while shRNAs expressed from integrated pol III promoter 
plasmid vectors in viral vectors, are delivered via viral infection (Sioud 2005a). 
Synthetic siRNA and siRNA conjugates are delivered to the cytoplasm, whereas 
plasmid- and virus-based shRNA vectors are delivered to the nucleus (Sioud 2005a). 
A drawback with synthetic siRNA delivery, is its transient nature in comparison with 
vector based delivery (Elbashir et al. 2001b; Holen et al. 2002). 
Choosing siRNAs for specific gene silencing is an empirical process, as the rules that 
govern efficient siRNA-directed silencing are still unknown. In mammalian cells 
siRNA-based RNAi is known to vary considerably depending on target sequence of 
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the siRNA (Leirdal et al. 2002; Holen 2003). For example, suppression of the PKCα 
gene expression by various siRNAs directed at different sites, varies from 0% to 90% 
(Leirdal et al. 2002). There has been much focus on siRNA primary structure as 
factor influencing RISC assembly and therefore siRNA activity, but several 
experiments have illustrated that also target mRNA secondary structure influences 
siRNA activity (Overhoff et al. 2005).  
 
Several groups have proposed sets of guidelines that seek to narrow the choices of 
siRNAs that could potentially silence specific gene expression, based on statistical 
data and theoretical assumptions. Early on, recommendations was given for the 
selection of siRNA target sites: The selected region should preferably be located in 
the coding region, at least 50 nucleotides downstream of the start codon; the GC-
content should be approximately 50% and sequence motifs AAN19TT was suggested 
to be advantageous (Elbashir et al. 2001b). Also, intronic sequences, 3’-UTR 
sequences and sequences that are known sites for the mRNA-binding proteins should 
be avoided (Martinez et al. 2002i; Dykxhoorn et al. 2003; Kawasaki et al. 2003). 
Notably, a Blast-search is necessary to ensure that the siRNA has no significant 
homologies with other genes than the intended target. The siRNAs used in this study 
were designed based on a set of rules for rational siRNA design described by Ui-Tei 
et al.(Ui-Tei et al. 2004). These rules were made observing synthetic siRNA activity, 
not shRNA based, vector delivered siRNA activity, as in this study. 
1.8 Therapautic potential of siRNAs 
Considering the ability of siRNA to knock down specific genes, and that only a few 
molecules per cell can trigger a potent effect (Montgomery et al. 1998), RNAi may 
become a major tool in therapy of a variety of diseases including viral infections, 
cancers and immunological diseases. There have been performed several experiments 
that demonstrate the therapeutic potential of siRNAs: 
 19
Production of HIV-1 virus was reduced when infected lymphocyte cells were 
transfected with siRNAs targeting either mRNAs encoding major regulatory HIV-1 
genes or cell receptors required for HIV-1 infection (Capodici et al. 2002; Jacque et 
al. 2002; Novina et al. 2002; Martinez et al. 2002iii).  Hepatite C virus, human 
papilloma virus and the SARS-CoV (severe acute respiratory-associated coronavirus) 
have been targeted successfully by siRNAs (Jiang et al. 2002; Randall et al. 2003; 
Zhang et al. 2004). Also, poliovirus, rous sarcoma virus and γ herpesvirus were 
targeted by siRNAs (Gitlin et al. 2002; Hu et al. 2002; Jia et al. 2003). A major 
concern with viruses may be the emergence of viral siRNA resistance, but this 
problem may be solved by targeting several viral sequences at once (Sioud 2004).  
Different oncogenes have been targeted, such as p53 and Ras (Brummelkamp et al. 
2002b; Martinez et al. 2002ii). In laukaemic cells, the BCR-ABL (breakpoint cluster 
region- Abelson protooncogene) oncogene has been targeted successfully (Wilda et 
al. 2002). Notably, siRNA can be used alone or in combination with existing cancer 
chemotherapy, when the cancerous cells have acquired resistance to existing drugs 
(Sioud 2004). Candidates for silencing in combinational therapy that are known to be 
involved in acquired chemotherapy resistance, are the genes MDR1 and Bcl-2. They 
have already been targeted successfully by siRNAs (Tsuruo et al. 2003; Wu et al. 
2003; Sioud 2004; Fu et al. 2005). 
In principle, any disease that involved abnormal gene expression can be target by 
siRNAs. Inflammatory, allergic and immunoregulatory disorders may be treated by 
targeting chemokine receptors involved in these disorders. Also, cytokines that are 
involved in immune diseases, such as TNF-α, may be targeted (Tracey et al. 1994; 
Sioud 2004; Stanislawska et al. 2005).  
Delivery is a challenge if siRNAs are to be used therapeutically. Excitingly, delivery 
in vivo in mice was achieved by cationic lipid-mediated delivery (McCaffrey et al. 
2002; Sioud et al. 2003). Also, a technique to target specific cell surface proteins in 
vivo has been demonstrated, using protamine to bind siRNAs to targeting antibodies 
(Song et al. 2005). Despite the success of siRNA-mediated inhibition of gene 
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expression in vitro and some animals, clinical application in humans represents a 
substantial challenge because of the delivery problem. Likewise, targeted delivery to 
specific cell or tissue types is still a challenge.  
1.9 The aim of the study 
The aim of the study was to investigate siRNA primary structure influence on 
activity, and to establish a technique of cell surface protein specific siRNA delivery 
by peptides. Several siRNAs were designed based on published design criteria, to 
target the HER2 oncogene. Our intent was to select an active siRNA after cloning 
different siRNA encoding vectors and studying their effects in transfected human 
cancer cells. Once an effective siRNA had been selected, it would be delivered 





2. Materials and Methods 
2.1 An overwiev 
Synthetic deoxynucleotides encoding siRNAs and containing the appropriate 
restriction half-sites (BamHI and HindIII) were annealed and a small aliquot was 
analysed by PAGE in order to verify the formation of DNA duplexes. The annealed 
oligonucleotide was cloned in the plasmid vector pRNA-H1.1/Neo (GenScript). After 
ligation, the mixture was transformed into E.coli cells. Plasmid DNA was isolated 
from several clones, and the presence of the siRNA encoding inserts was verified by 
digestion with BamHI and HindIII restriction enzymes, followed by PAGE analysis. 
Positive clones were sequenced to rule out mutations in siRNA sequences. Plasmid 
vectors encoding three siRNAs (E1, E2 and E3) targeting the oncogene HER2, were 
investigated by transfecting them into the breast cancer cell line SKBR3 (ATTC). 
The potencies of the siRNAs were examined by flow cytometry, western and 
northern blots. 
2.2 Chemicals and reagents 
2.2.1 Antibodies 
Actin-ab solution: 1:2000 Actin ab (I-19) goat polyclonal IgG (Santa Cruz 
Biotechnology) and 1% w/v dry milk (Tine) in PBST. 
HRP/anti-goat-ab solution: 1:5000 µl Polyclonal Rabbit Anti-Goat 
immunoglobulins/HRP (Dako Cytomation) and 1% w/v dry milk (Tine) in PBST. 
HRP/anti-rabbit-ab solution: 1:5000 µl Polyclonal Goat Anti-Rabbit 
immunoglobulins/HRP (Dako Cytomation) and 1% w/v dry milk (Tine) in PBST. 
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Irrelevant-ab solution: 4% Negative control, mouse IgG1 (Dako Cytomation) in 
Flow-buffer. 
Monoclonal HER2-ab solution: 2% Neu (9G6), mouse monoclonal IgG1 (Santa Cruz 
Biotechnology) in Flow-buffer. 
PE/secondary-ab solution: 0,4% Goat anti-mouse Ig(H+L)-RPE (Southern 
Biotechnology Associates) in Flow-buffer. 
Polyclonal HER2-ab solution: 1:2000 Neu (C-18) rabbit polyclonal IgG (Santa Cruz 
Biotechnology) and 1% w/v dry milk (Tine) in PBST. 
2.2.2 Buffers and solutions 
Blotting buffer, 10x : 25 mM Trisma base (Sigma), 192 mM glycine (Fluka), 20% v/v 
methanol (Ratburn Chemicals) 
Denhardt’s reagent, 50x : 1% w/v Ficoll® 400 (Sigma), 1% w/v 
polyvinylpyrrolidone (Sigma), 1% w/v  BSA (Sigma), filtered 
DEPC-treated water: dH2O with 0,1% v/v DEPC (Sigma), left overnight and 
autoclaved. 
DTT-Loading buffer, x3 : 136 mM Trisma base (Sigma) , 90 mM DTT (Sima), 5,5 % 
w/v SDS (Bio-Rad), 0,2 % w/v BPB (Fluka), 13,5 % v/v glycerol (AppliChem), pH 
6,8 (store at –20°C) 
EtBr-solution: 1‰ w/v EtBr (Sigma) 
Flow-buffer: 1% v/v FCS (Cambrex) in PBS 
Loading buffer 3x : 50 % v/v glycerol (Applichem), 0,2% w/v BPB (Fluka), 1x 
Phosphate-buffer 
Lysation-buffer: 1% v/v Protease inhibitor (Sigma), 0,4 % v/v IGEPAL (Sigma-
Aldrich) in PBS 
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PBS: 137 mM NaCl (Riedel-de Haën), 2,7 mM KCl (Fluka), 10 mM Na2HPO4 
(Fluka), 2mM KH2PO4 (Fluka), pH 7,4 
PBST: 0,05% Tween (Sigma-Aldrich) in PBS 
Phosphate-buffer, 10x : 200mM Na2HPO4 (Fluka), NaH2PO4 (Fluka) to pH 7,0 , 
autoclaved 
RB, 10x :  10 mM EDTA (Fluka), 50 mM NaAc (Merck), 4‰ w/v NaOH (Fluka), 
200 mM MOPS (Sigma), pH 7,0 (autocalaved before addition of MOPS)  
RH-buffer, 1x : 10% w/v dextran sulphate (Amersham Pharmacia Biothech), 2% w/v 
SDS, 5x SSPE, 1x Denhardt’s reagent 
Sample buffer, 3x : 66% v/v deionised formamide (Prolabo), 7,8% v/v formaldehyde 
(Fluka), 1,3x Phosphate-buffer  
S-RB, 10x : 25 mM Trizma base (Sigma), 200 mM glycine (X), 0,1% w/v SDS (X), 
pH 8,3 
SSC, 20x : 175,3‰ w/v NaCl (Riedel-de Haën), 88,2‰ w/v sodium citrate (Fluka), 
autoclaved, pH 7,0  
SSPE, 20x : 175,3‰ w/v NaCl (Riedel-de Haën), 23,5‰ w/v NaH2PO4 (Fluka), 
7,4‰ w/v EDTA, autoclaved, pH 7,4 
TAE, 1x : 40 mM Trizma base (Sigma), 40 mM glacial acetic acid (Fluka), 1 mM 
EDTA (Fluka), pH 8,0 
TBE, 5x : 0,45 M Trizma base (Sigma), 0,45 M boric acid (Riedel-de Haën), 10 mM 
EDTA (Fluka), pH 8,3 
Tris-HCl: 20mM Trizma base (Sigma), titrated with HCl (Fluka) to pH 8,8 or 6,8  
 Washing buffer: 0,1 w/v % SDS (Bio-Rad) in 1x SSC 
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2.2.3 Mediums 
Complete medium: RPMI 1640 medium (PAA Laboratories) with 6%v/vFCS 
(Cambrex) and 1x Penicillin Streptomycin (PAA Laboratories) 
LA: 10‰ w/v Trypton (Beckton Dickinson), 5‰ w/v yeast extract (Beckton 
Dickinson), 10‰ w/v NaCl (Riedel-de Haën), 15‰ w/v agar (Oxoid) 
LB-medium: 10‰ w/v Trypton (Beckton Dickinson), 5‰ w/v yeast extract (Beckton 
Dickinson), 10‰ w/v NaCl (Riedel-de Haën) 
2.3 Culturing of bacterial and human cells 
E.coli cells (Invitrogen) were grown in LB-medium. Alternatively, the cells were 
grown on plates with LA. When positive selection of ampicillin resistant bacteria was 
needed, LA with 0,1‰ w/v ampicillin (Bristol-Meyers Squibb) was used.  
SKBR3 cells were obtained from ATTC and maintained according to the suppliers 
instructions. They were maintained in Complete medium and plated in tissue culture 
flasks (75 or 162 cm2, Costar) at 50-80% confluence. For subculturing, the medium 
was removed; 4 ml Trypsin-EDTA Solution (Sigma-Aldrich) was added, and then the 
cells were incubated for 2 min at 37°C. Subsequently, the flask was jolted forcefully, 
10 ml new Complete medium were added, and the cells were transferred into a 15 ml 
Falcon tube, and centrifuged for 5 min at 1,2x103 rpm (Eppendorf Centrifuge 
5810R). The culture medium was removed and the cells were resuspended in 2 ml 
Complete medium. Cell concentration was estimated by the Z1 Coulter® Particle 
counter (Beckman Coulter), using Coulter® Isotone II Diluent (Beckman Coulter) as 
dilutant and Zap-oglobin® II (Beckman Coulter) for cell lysation.    
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2.4 Electrophoresis 
Electrophoresis is a technique based upon the principle that charged molecules placed 
in an electric field, will migrate towards the electrode with the opposite charge. In a 
gel, which consists of a complex network of pores, the rate at which molecules moves 
will be determined by its ability to penetrate through this network. This ability will in 
most cases reflect the size of the molecule (Dale 2002). 
2.4.1 Agrose Gel Electrophoresis 
Agarose (Invitrogen) gels (1,5%) were used to analyze and separate large DNA 
molecules, such as plasmids. To visualize DNA by UV-light, EtBr-solution was 
added to the gel solution prior to casting. For electrophoresis buffer, 1x TAE buffer 
was used, and the DNA samples were mixed with 1/3 v/v Loading buffer, before 
loading them onto the gel. In some cases, DNA was purified from the gels using the 
Concert Rapid Gel extraction kit (Life technologies) according to the supplier’s 
instructions. 
2.4.2 Formaldehyde-Agrose Gel Electrophoresis 
RNA for northern blotting was analysed using 1% formaldehyde-agarose gels. The 
gel solution was made by mixing 0,5g agarose (Invitrogen), 5ml 10x RB and 36 ml 
dH2O. After boiling, the mixture was cooled down to about 50°C and then 9 ml form-
aldehyde was added (taking precautions against the formaldehyde). Samples were 
mixed with Sample buffer (1/3 v/v), heated to 65°C for 10 min and then 1/3 v/v of 
loading buffer containing 5% v/v EtBr-solution was added.  Electrophoresis was run 
at 4°C in 1x RB. 
2.4.3 PAGE 
Polyacrylamide Gel Electrophoresis (PAGE) was used to analyse small DNA 
fragments (~100 bp). Samples were electrophoresed  in 16% polyacrylamide gels.  
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Gels were made by mixing 4 ml 40% Acrylamide (USB Corporation), 3 ml 5x TBE, 
3ml dH2O, 50 µl 10% APS (Bio-Rad) and 10µl TEMED (Bio-Rad). The same 
Loading buffer was used as for agarose gels (section 2.4.1). Electrophoresis was run 
in 1x TBE-buffer. For DNA visualisation in UV-light, the gel was bathed in ~2dl 
dH2O with a few drops of EtBr-solution. 
2.4.4 Urea-PAGE 
For analysis of oligonucleotides, PAGE gels with 7 M Urea were used, to prevent. 
secondary structures. The gel solution was made by mixing 4 g Urea (Invitrogen) 
with 4ml 40% Acrylamide (USB Corporation) and 3 ml 5x TBE. This was stirred in 
37 °C, until all the urea had dissolved. Subsequently, 50 µl 10% APS (Bio-Rad) and 
10µl TEMED (Bio-Rad) were added. Further, electrophoresis was run as described in 
section 2.4.3. 
2.4.5 SDS-PAGE  
SDS-PAGE was used to separate proteins for western blots. Each gel was made by 
mixing 3,75 ml 20mM Tris-HCl pH 8,8 , 0,1 ml 10% SDS (Bio-Rad), 2,5 ml 40% 
Acrylamide (USB Corporation), 3,6 ml distilled water, 50 µl 10% APS (Bio-Rad) 
and 5 µl TEMED (Bio-Rad ). The stacking gel for SDS-PAGE was made by mixing 
630 µl 20mM Tris-HCl pH 6,8 , 50 µl 10% SDS (Bio-Rad), 600 µl 40% Acrylamide 
(USB Corporation), 3,7 ml distilled water, 25 µl 10% APS (Bio-Rad) and 5 µl 
TEMED (Bio-Rad). Proteins samples were mixed with mixed with 1/3 v/v DTT -
loading buffer, denatured by heat (95°C, 5 min) and applied onto the gel. 
Electorphoresis buffer for SDS-PAGE was 1x S-RB. 
2.5 SiRNA design and cloning 
The siRNAs targeting HER2 used in this study were named E1, E2 and E3 (ErbB2 
silencing siRNA 1, etc.). They were designed to target the following site sequences 
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within the HER2 mRNA: 5’GAGUUGGUGUCUGAAUUCU3’ (E1), 
5’GCCUCACAGAGAUCUUGAA3’ (E2) and 5’GGGACGAAUUCUGCACAAU3’ 
(E3). The siRNAs were designed based on the recommendations described by Ui-Tei 
et al. were taken into consideration: (i) A/U at the 5' end of the antisense strand; (ii) 
G/C at the 5' end of the sense strand; and (iv) the absence of any GC stretch of more 
than 9 nt in length (Ui-Tei et al. 2004). The third rule: (iii) at least five A/U residues 
in the 5' terminal one-third of the antisense strand, is only followed by E1; it has five 
A/U residues within the six last positions of the DNA sense strand. 
DNA sequences encoding these siRNAs were imbedded in larger oligonucleotide 
constructs encoding shRNA: An antisense region of 19 nt, was followed by a hairpin-
forming region of 10 nt, a sense region of 19 nt and a poly-thymidine site that is 
recognised by RNA polymerase III as a stop codon (Fig.4). Antisense versions of 
these oligonucleotides strands were annealed to the sense strands, to form double -
stranded DNA constructs (see Fig.4). The annealed constructs contained BamHI and 
HindIII restriction half-sites. All oligonucleotides were purchased from Eurogentec. 
 
Figure 4: DNA construct encoding E1 shRNA. The upper sequence is the 
sense strand, and the lower sequence the antisense strand.   
To anneal the sense and antisense constructs, oligonucleotide solutions (100 μM), 1 
μl from each, was mixed with 88 µl dH2O and 10 µl 10x Buffer for T4 DNA Ligase 
(New England Biolabs). This was heated on a heat block on 95°C for 5 min. The heat 
block was then turned off and the solution was left to cool for 2 hours. As a control, 
the annealed construct was inspected by Urea-PAGE, running it against un-annealed 
oligonucleotides. 
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Plasmid vector pRNA-H1.1/Neo (GenScript) contains the E.coli origin of replication 
pUC, an ampicillin resistance gene, and the human RNA polymeraseIII promoter H1 
upstreams for a polylinker with BamHI and HindIII restriction sites. This plasmid 
was digested with HindIII and BamHI restriction enzymes, using the following 
protocol: 20 µl 150 ng/µl pRNAT-H1.1/Neo (GenScript) was mixed with 2,5 μl 10x 
NEB2 (New England Biolabs), 0,5 µl 100x BSA (New England Biolabs), 1,0 μl 10 
kU/ml HindIII (New England Biolabs) and 1,0 μl 10 kU/ml BamHI (New England 
Biolabs). The mixture was incubated at 37°C for 3 hours. The digested plasmid DNA 
was purified from an agarose gel as described in section 2.4.1. The digestion was 
verified by running the digested plasmid against undigested plasmid on agarose gel. 
Plasmid DNA concentration was measured by a GeneQuant II spectrophotometer 
(Pharmacia Biotech) at 260 nm. The annealed DNA constructs were ligated into 
BamHI and HindIII digested pRNA-H1.1/Neo, using the following protocol: 15,5 µl 
distilled water was mixed with 0,5 µl 50 ng/µl digested pRNAT-H1.1/Neo and 1,0 µl 
0,5 µM annealed construct. This was heated to 65°C in 5 min, cooled on ice and 
added 2 µl 10x Buffer for T4 DNA Ligase (New England Biolabs) and 1 µl 400 
kU/ml T4 Ligase (New England Biolabs). Samples were incubated overnight at 16°C.  
DH5α E.coli cells (Invitrogen) where made competent using the following protocol: 
A 5 ml E.coli culture was grown overnight. One ml of this culture was added 20 ml 
LB-medium and incubated for approximately 2 hours, after which the culture was 
only just transparent. The culture was centrifuged for 5 min at 5x103 rpm and 4°C 
(Eppendorf Centrifuge 5810R), and pellet was re-dissolved in 10 ml ice cold 50 mM 
CaCl2 (Fluka). This was incubated for 40 min on ice, and subsequently centrifuged 
for 5 min at 5x103 rpm and 4°C (Eppendorf Centrifuge 5810R). The pellet was 
dissolved in 2 ml ice cold 50 mM CaCl2.  
The now competent cells were transformed by adding 3 µl ligation mixture to 50 µl 
cells. As a negative control, 50 µl competent cells were added 300 µg BamHI and 
HindIII-digested pRNA-H1.1/Neo plasmid. After 30 min on ice, the samples were 
given a heat chock of 42°C for 30 seconds, and then put back on ice and left for 1 
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min. The samples were added 900 µl LB-medium each and incubated at 37°C for 1 
hour, with rotation. After centrifugation for 2 min at 2x103 rpm (Eppendorf 
Centrifuge 5810R), pellets were dissolved in 150 µl LB-medium each, plated on agar 
plates with ampicillin, and incubated overnight at 37°C.  
The day after, colonies were collected and 3 ml cultures were made from each of 
them in LB-medium (with 0,1‰ w/v ampicillin). Plasmid was then isolated from the 
cultures using QIAprep® Spin miniprep kit (Qiagen), and concentrations of plasmid 
were measured by GeneQuant II spectrophotometer (Pharmacia Biotech) at 260 nm. 
To detect the presence of siRNA encoding inserts, volumes corresponding to150 ng 
from each plasmid preparation were digested with BamH1 and Hind III restriction 
enzymes and then analysed by PAGE.A large LB-culture (50 ml) of the cells from 
one of the colonies was made, and the plamid was isolated from this by HiSpeed® 
Plasmid maxiprep kit (Qiagen). Plasmid concentration was measured with the 
GeneQuant II spectrophotometer at 260 nm.  
2.6 Sequencing 
The technique of DNA sequencing involves a DNA polymyrase chain reaction (PCR) 
on the DNA template that is going to be sequenced. In addition to deoxynucleotides, 
the reaction solution contains dideoxynucleotides, which terminates replication. The 
four different dideoxynucleotides are labelled with four different fluorescent dyes, 
which can be detected by an automatic sequencing machine. By comparing 
polymerised fragment sizes and their fluorescence, the machine can deduce template 
sequence (Dale 2002). 
Plasmid DNAs from the positive clones were sequenced using the DigDye 
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems), adding 5% 
v/v glycerol (AppliAhem) to the sample mixture before the PCR, to prevent 
unwanted secondary structures. A forward primer 
(5’TAATACGACTCACTATAGGG3’) that anneals upstreams of the construct insert 
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was used. PCR was carried out on the programmable thermal cycler GeneAmp® 
PCR System 9700 (Applied Biosystems), using the program: 98°C; 2 min, 27 times 
(96°C; 30 s, 55°C; 15 s, 60°C 4 min), then 4°C. Automatic sequencing was done on 
an ABI Prism 310 Genetic Analyzer (Applied Biosystems), and sequencing data was 
analysed by Chromas 2.3 computer software. 
Vectors encoding E2 and E3 were ligated, cloned and sequenced by other members 
of the group, in the same way as described above.  
2.7 Transfection 
One day prior transfection, SKBR3 cells were plated in 6 well cell culture clusters 
(Costar) at  3x105 cells per well. After 18 hours culture at 37°C, cells were 
transfected with expression vectors in 6-well plates using Lipofectamine reagent 
(Invitrogen). Cells were transfected with the following molecules: E1-vector, E2-
vector, E3-vector, pEGFP-N3 (Clontech) encoding GFP, synthetic E3, and synthetic 
siRNA (against TNF-α) conjugated with FITC. Volumes corresponding to 2µg vector 
(4µg for synthetic siRNA), were mixed with 100 μl RPMI each. Each of the solutions 
were then mixed with 100 µl of the previously made Lipofectamin solution and 
incubated for 15 min. The wells with the cells were washed several times with RPMI, 
and then left with 1 ml RPMI. The lipofectamin-vector solutions were then added to 
the wells. As controls, some wells were left without any addition. The cells were 
incubated at 37 °C for 4 hours, 1 ml Complete medium was subsequently added to 
each well and the cells were then incubated at 37°C for 44 hours. 
2.8 Flow cytometry analysis 
Flow cytometry is a technique for making rapid measurements of particles or cells as 
they flow in a fluid stream one by one through a sensing point. Flow cytometers 
make measurements based on light as the source of exitation. The scattered and 
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fluorescent light generated by cells passing through the illuminating beam is collected 
by photodetectors, which convert the photon pulses into electronic signals (Ormerod 
2000). Light scattered forwards from a cell is proportional to cell size, and light 
scattered sidewards from a cell is proportional to granulation in the cell. Typical 
fluorescent dyes are fluorescine isothiocyanate (FITC) and phycoerythrin (PE). When 
these molecules are conjugated to monoclonal antibodies specific for a protein, they 
can be applied for cell protein expression measurement. Collected flow cytometric 
data are commonly displayed in the form of frequency histograms and dual-parameter 
correlated dot plots. The frequency histogram is a direct graphical representation of 
the number of events against intensity. The dot plot is a two-dimensional extension of 
the frequency histogram where each cell is represented at the co-ordinates appropriate 
to the measured values (Ormerod 2000).  
To assess the activity of the siRNAs, surface expression of HER2 was analysed by 
flow cytometry.  Untransfected and transfected cells were carefully scraped off the 
bottom with a cell-scrape, and they were transferred into 15 ml tubes. Cell numbers 
were determined by Z1 Coulter® Particle counter   (Beckman Coulter).  Cells were 
centrifuged for 5 min at 1,2x103 rpm and 4°C (Eppendorf Centrifuge 5810R) and 
then washed once in cold Flow-buffer (kept on ice). Volumes corresponding to 105 
cells were transferred to V-bottomed wells in a 96 well cell culture cluster (Costar); 
three wells from each sample were filled. The plate was then centrifuged (5 min, 
1,2x103 rpm, 4°C, Eppendorf Centrifuge 5810R). After centrifugation, supernatants 
were carefully removed, and the plate was vortexed slightly.  
Staining was done by filling one well from each probe with 100 μl Monoclonal 
HER2-ab solution and one well from each probe with 100 μl Irrelevant-ab solution. 
The remaining wells were filled with 100 μl Flow-buffer each. The pellets were re-
dissolved, and the plate was wrapped in alum foil and kept on ice for 30 min. After 
this, the plate was centrifuged (5 min, 1,2x103 rpm, 4°C, Eppendorf Centrifuge 
5810R), and the supernatants were subsequently carefully thrown off. The pellets 
were washed twice in 100 μl Flow-buffer (cold), before PE/secondary-ab solution 
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was added to the cells formerly treated with Monoclonal HER2-ab and Irrelevant-ab, 
100 µl in each well. To each of the remaining wells 100 μl Flow-buffer were added. 
The pellets were dissolved, and the plate wrapped in alum foil and kept on ice for 30 
min.  
After this, the plate was centrifuged (5 min, 1,2x103 rpm, 4°C, Eppendorf Centrifuge 
5810R), and the pellets were washed twice in 100 ml cold Flow-buffer each.  The 
pellets were then dissolved in 200 μl Flow-buffer, decanted to 5 ml round bottom 
tubes (Becton Dickinson), before analysing them by a FACSCalibur flow cytometer 
(Becton Dickinson), counting 5000 cells from each sample. Flow cytometry data was 
processed using FlowJo 5.7.2 computer software. 
2.9 Western blot analysis 
Western blotting is used for detection of specific proteins, and relies on protein 
separation by SDS-PAGE and detection by specific antibodies. Following separation 
of a cytoplasmic extract by SDS-PAGE, the proteins are transferred to a membrane 
by running a perpendicular current through the gel into the membrane (the proteins 
are given charge by SDS). Unspecific binding by specific antibodies is prevented by 
first blocking the membrane with an agent containing unspecific antibodies, such as 
milk. The membrane is then treated with specific antibodies, and these can either be 
labelled themselves, or detected by a second labelled antibody. The technique will 
identify not just the presence or absence of proteins that reacts with the antigens, but 
also its sizes and estimates of relative expression levels (Dale 2002). In this study, 
primary antibodies against HER2 and β-actin were used, together with secondary 
antibodies conjugated with the enzyme Horse raddish peroxidase (HRP). When 
treated with its substrate, this enzyme emits light that is detectable by a photographic 
film. β-actin was used as reference since there are abundant levels of this protein in 
eukaryote cells. 
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Protein extracts from transfected and untransfected cells were prepared using the 
following protocol: The cells were carefully scraped off the wells with a cell-scrape, 
decanted to 15 ml tubes and then centrifuged for 5 min at 2x103 rpm. Each cells pellet 
was washed once in 400 μl PBS, resuspended in 20 µl Lysation-buffer, and then 
incubated on ice for 20 min. Subsequently, samples were centrifuged (10 min, 2x103 
rpm, Eppendorf Centrifuge 5810R). The supernatants (cytoplasmic extracts) were 
transferred into 1,5 ml eppendorf tubes. Protein amounts were determined with the 
Bio-Rad Protein Assay (Bio-Rad). Spectrophotometry (UV-1601, Shimadzu) at 
595nm, was used. Absorbances of various γ-globulin (Octapharma) concentrations 
were measured to make a standard curve. For each condition, 15 µg cytoplasmic 
proteins were separated on 10% SDS-PAGE.  To estimate protein molecular weights, 
the Precision plus protein marker (Bio-Rad) was used. 
After electrophoresis, proteins were transferred to a nitrocellulose membrane 
(Whatman Schleicher & Schuell), using 1x Blotting buffer and a perpendicular 
current of 100V and magnet stirring, for one hour, at 4°C. The membrane was 
blocked in 5% w/v dry milk solution for 1 hour with slow rotation. Based on the 
protein marker, the membrane was cut into two parts; one containing HER2 and the 
other β-actin. The HER2 part was put in Polyclonal HER2-ab solution, whereas the 
actin part was put with Actin-ab solution. The membrane pieces were incubated for 
90 min with slow rotation. After this, the pieces were washed in PBST for 30 min 
with fast rotation, with the PBST (~1dl) changed every 10th minute. After washing, 
the HER2 part of the membrane was incubated in HRP/anti-rabbit-ab solution, and 
the actin part in HRP/anti-goat-ab solution, for 1 hour with slow rotation. 
Subsequently, the pieces were washed in PBST for 30 min with fast rotation, with the 
PBST (~1dl) changed every 10th minute. Reactive β-actin and HER-2 proteins were 
revealed with ECL Westtern blotting analysis system (Amsterdam Biosciences) and 
photographic film. The intensities of the protein-bands were measured using 
ImageQuant 5.2 computer software. 
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2.10 Northern blot analysis 
Northern blot is a method for detecting specific mRNA, and relies on hybridisation to 
specific labelled probes. A Northern blot involves electrophoretic separation of a 
purified extract of RNA from cells, followed by immobilisation onto a membrane and 
hybridisation with a specific DNA probe (Dale 2002). Unspecific hybridisation is 
prevented by first pre-hybridising the membrane with an agent containing unspecific 
DNA, such as salmon sperm DNA. If the probes are made radioactive, mRNA can be 
detected by phosphoimaging. The technique will identify not just the presence or 
absence of mRNAs that hybridise with the probes, but also its relative expression 
levels. 
Total RNA extracts from transfected and untransfected cells were prepared using the 
following protocol: The cells were lysed by adding 1 ml TRIzol® Reagent 
(Invitrogen) and incubated for 5 min at 25°C. Subsequently, 200µl chloroform 
(Prolabo) was added to each sample (taking precautions against the chloroform), 
mixing well. The samples were incubated for 3 min at 25°C, and then centrifuged for 
15 min at 2x103 rpm and 4°C (Eppendorf Centrifuge 5810R). The upper aqueous 
phases were added 0,5 ml propanol-2 (Prolabo) each, incubated for 10 min at 25°C, 
and then centrifuged for 10 min at 2x103 rpm and 4°C (Eppendorf Centrifuge 
5810R). RNA pellets were washed in 1 ml 75% rectified ethanol (Arcus), air-dried, 
and then dissolved in 15µl DEPC-treated water each. RNA concentrations were 
measured by GeneQuant II spectrophotometer (Pharmacia Biotech) at 260 nm. 
Total RNAs (5 µg/ sample) were analysed by formaldehyde-agarose gel 
electrophoresis. After electrophoresis, RNA was transferred to a Hybond-N+ 
membrane (Amsterdam Biosciences) by upward capillary transfer, using 20x SSC. 
The membrane was then air-dried and subsequently exposed to UV-light, 3 min on 
each side, to fix RNA. 
Hybridisation with mRNA-specific probes was done using the following protocol: 
The membrane was placed on a mach and moistened with Washing buffer at 65°C, 
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with rotation. One 100 µl of Salmon sperm DNA, preheated at 95°C for 5, were 
added to the prehybridization solution. Pre-hybridisation was done for 2 hours at 
65°C, with rotation.  The DNA probes were labelled with 32P-dCTP using the 
Rediprime II DNA Labelling System, according to the manufactere’s instructions 
(Amersham Biosciences). Free 32P-dCTP was removed by column centrifugation 
using Sephadex G-50 Medium (Amersham Pharmacia Biotech) and a GS-6KR 
Centrifuge (Beckman) at 2,5x103 rpm for 5 min. Purified probes were heated to 95°C 
for 10 min, and subsequently added to the pre-hybridisation mixtures. The membrane 
was hybridised over night at 65°C, with rotation. The next day, it was washed thrice 
in Washing buffer; buffer from the first wash was disposed of in radioactive waste. 
Hybridisation signals were visualised by phosphoimaging, using a Storm 860 
(Molecular Dynamics). Intensities of the radioactive signals were measured using 
ImageQuant 5.2 computer software. Because HER2 and actin mRNAs have very 
different sizes, the same membrane was also hybridised with an actin DNA probe 
without membrane stripping. 
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3. Results 
3.1 Cloning results 
E1 encoding DNA construct strands were annealed and then analysed by PAGE with 
7 M Urea (Fig.5). Although there are some distortions in the bands, one can assume 
that the annealing have succeeded because the band from the annealing reaction 
exhibited higher molecular weight than that of the unannealed oligonucleotides. 
 
Figure 5: Analysis of annealing reaction by Urea-PAGE: a) E1 construct –
sense, b) E1 construct –antisense, c) Annealed E1 construct. 
The pRNATH1.1/Neo plasmid was used as cloning vector. In these experiments, the 
plasmid was digested by BamHI and HindIII restriction enzymes, purified by gel 
extraction, and then analysed by agarose gel electrophoresis against undigested 
plasmid. The data indicated that the plasmid digestion was complete.  
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Annealed E1oligonucleotide constructs were ligated into BamH1- and Hind III- 
digested pRNATH1.1/Neo plasmid.  The ligation mixture was transformed into 
chemically competent DH5α E.coli cells. Transformed E.coli were plated on agar 
plates containing ampicillin. E.coli cells transformed with only the digested plasmid 
were also included as a negative control. After incubation at 37°C, only 4 colonies 
were obtained (negative control was negative). Plasmid DNA was prepared from 
each clone, digested with BamHI and HindIII and then analysed by PAGE. All the 
four colonies contained insert as shown in Fig 6.  
 
Figure 6: Analysis of the BamHI and HindIII restricted recombinant plasmid 
from colonies 1 to 4. The positive clones contain the siRNA-encoding 
inserts as indicated by the arrow. 
Based on the data shown in Fig.6, we assumed that the E1 encoding fragment was 
successfully ligated into the pRNATH1.1/Neo plasmid vector.  Subsequently, a large 




3.2 Sequencing results 
To confirm the identity of the inserted fragment, sequence analysis was performed on 
plasmid DNA from colony number 1. The data shown in Fig.7 indicated that the 
siRNA insert is located between 137 and 197 positions. The sequencing data align 
perfectly with the E1 oligonucleotide construct, with no mismatches, as shown in 
Fig.8. This verifies that no mutation has occurred in the E1 encoding part of the 
plasmid vector. Cloning and sequencing of vectors encoding E2 and E3, done by 




Figure 7: Chromatogram of siRNA encoding part of recombinant plasmid. 
Position numbers are shown above. 
 
 
Con    1 -----------------GATCCCGAGTTGGTGTCTGAATTCTTTGATATCCGAGAATTCA 
Seq  120 CTGTATGAGACCACTCGGATCCCGAGTTGGTGTCTGAATTCTTTGATATCCGAGAATTCA 
Con   44 GACACCAACTCTTTTTTA------------------------------------------ 
Seq  180 GACACCAACTCTTTTTTAAGCTTAAGTTTAAACCGCTGATCAGCCTCGACTGTGCCTTCT 
 
 
Figure 8: E1 sense construct (Con) aligned with the plasmid sequence 




3.3 Flow cytometry results 
Cells were transfected with E1, E2 and E3 expression vectors for 48 hours, and then 
the expression of HER2 was examined with flow cytometry. In total, four 
transfection experiments were performed for each construct. Noise data were 
excluded by gating away small cells in dot plots of forward scatter against side 
scatter, with the same gate (R1) used in all four experiments (example shown in 
Fig.9). Flow cytometric data is expressed as relative values, hence no unit of 
measure. 
 
Figure 9: Dot plot of untransfected cells from the first flow cytometric 
experiment. Cells present in gate R1 were analysed further. Colours, 
ranging from blue to red indicate densities of dots. 
The first experiment showed apparent silencing effects (see Fig.10). Median 
fluorescences were calculated for the samples, and percentage reduction of 
fluorescence for the transfectants were calculated relative to untransfected cells 
(Table 1). E1 exhibited the lowest effect, whereas E2 and E3 exhibited a similar 
inhibitory effect. Cells treated with only the vector (pRNATH1.1/Neo), were not 
included as a negative control in the first experiment.  However, if we consider E1 as 
a negative control (inactive siRNA), the data would indicate that E2 and E3 are 




Figure 10: Frequency histograms from the first flow cytometric experiment: 
Green histograms show stained transfected cells, red histograms show 






Table 1: Median of fluorescence for various samples in the first flow cytometric 
experiment. 
 
Median of fluorescence 
Percent fluorescence 
reduction  
 Untransfected 891,43  
 E3-vector transfected 600,43 32,6 
 E2-vector transfected 640,40 28,2 
 E1-vector transfected 762,07 14,5 
 
The two next transfection experiments analysed by flow cytometry showed no 
apparent silencing effect in the frequency histograms, and when reductions in median 
fluorescences were calculated, they showed enhancing effects (implying greater 
fluorescence for the transfectants).  
The fourth and last transfection experiment showed apparent silencing effects, but 
they were quite different from those in the first experiment (see Table 2).  Here 
untreated pRNATH1.1/Neo plasmid vector (vector only) was included, and showed a 
reduction in fluorescence of about 15%. Therefore, only fluorescence reduction 
exceeding this level of inhibition should be considered. Taking this into account, 
Table 2 implies silencing effects of about 15% for vector delivered E1 and synthetic 
E3. Vector delivered E3 shows no effect, and E2-vector shows a fluorescence 






Table 2: Median of fluorescence for various samples in the fourth flow cytometric 
experiment. 
 
Median of fluorescence 
Percent fluorescence 
reduction  
 Untransfected 326,57  
 Vector only transfected 278,93 15,6 
 E3-vector transfected 279,86 14,3 
 E2-vector transfected 343,13 -5,07 
 E1-vector transfected 234,63 28,2 
 Synthetic E3 transfected 235,32 27,9 
 
In the fourth flow cytometry experiment, transfections with GFP-encoding vectors 
and FITC-conjugated siRNAs were included, to measure levels of transfection. As 
shown in Fig.11, almost all cells treated with synthetic siRNA were positive, 
implying optimal transfection conditions.  In contrast, only 18% of the cells 
transfected with the plasmid encoding GFP were positive. Low transfection levels 









Figure 11: Dot plots indicating transfection levels in the fourth transfection 
experinent analysed by flow cytometry. Percentages of cells inside the 






 Table 3: Fluorescence due to unspecific staining in the four flow cytometric experiments. 
 1st 2nd 3rd 4th
 Untransfected 8,27 3,41 3,37 2,5 
 Vector only  - - 11,25 13,05 
 E3-vector  12,78 12,29 10,74 11,56 
 E2-vector  13,25 12,54 12,35 12,16 
E1-vector  10,68 10,86 11,23 10,81 
 
All four experiments showed about the same level of fluorescence due to unspecific 
staining, indicated by the results from staining with irrelevant antibodies (Table 3). 
As sown in Table 3, untransfected cells generally have lower median fluorescences 
due to unspesific staining. This might have masked silencing effects to some degree.   
3.4 Western blot results 
HER2 and β-actin expression in cancer cells transfected with E1, E2 and E3 encoding 
vectors, were analysed by western blotting. After cytoplasmic extraction, protein 
concentrations in the various samples were measured by spectrophotometry and γ-
globulin standard, so that volumes corresponding to 15 µg from each sample, could 
be loaded onto the western blot SDS-PAGE gel. This should have given the same 
actin-band intensities on the developed western blot film, so that HER2-band 




Figure 12: Western blot analysis of HER2 and actin levels in transfected 
and untransfected cells. The upper bands show HER2 and the lower bands 
β-actin. 
a) Untransfected cells 
b) Vector only transfected cells 
c) E3-vector transfected cells  
d) E2-vector transfected cells 
e) E1-vector transfected cells 
 
Table 4:  Intensity-ratios of protein bands from western blot analysis. 
 





a) Untransfected 11930958 2210283 5,40  
b) Vector only  6962797 1338886 5,20 3,7 
c) E3-vector  11278711 5015899 2,25 58,3 
d) E2-vector  10903927 2890235 3,77 30,1 
e) E1-vector  11841227 2166423 5,47 -1,3 
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As but as shown in Fig.12, similar actin-band intensities have not been achieved, 
most likely due to a loading problem. However, when intensities are expressed as 
ratios (Table 4), amount of proteins from each sample should not influence. 
According to Table 4, vector only and E1 do not exhibit significant HER2 silencing 
effects, whereas E3 has a silencing effect of about 60% and E2 has a silencing effect 
of about 30%.  
3.5 Northern blot results 
Levels of HER2 and actin mRNA in cells transfected with E1, E2 and E3 vectors, 
were analysed by northern blotting. Total RNAs from tranfectants were prepared 
using TRIzol® reagent, measured by spectrophotometry and subsequently samples of 
5 µg were analysed by formaldehyde-agarose gel electrophoresis. After blotting to a 
nylon membrane, the membrane was probed for HER2 and actin mRNAs (Fig.10). 
Despite  applying the same amount of total RNA, the data show a large variation in 
RNA concentrations, most likely due to inaccuracy in loading. Similar to western 
blot, the data was expressed as intensity ratios (Table 5). According to these results, 
the siRNA encoding vectors enhance HER2 expression in the transfected cells. 






Figure 13:Northern blot analysis of HER2 and actin mRNA levels in 
transfected and untransfected cells. The upper bands show HER2 mRNA 
and the lower bands actin mRNA. 
1) E1-vector transfected cells  
2) E3-vector transfected cells  
3) E2-vector transfected cells  
4) Vector only transfected cells  
5) Untransfected cells 
 
Table 5: Intensity-ratios of mRNA bands in northern blot analysis. 








Untransfected 587526 510608 1,15  
Vector only  347533 307233 1,13 1,7 
E3-vector  356740 280180 1,27 -10,7 
E2-vector  308272 224694 1,37 -19,2 
E1-vector  423016 327137 1,29 -12,4 
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4.  Discussion 
Specific gene inactivation by siRNAs has great potential to dissect gene function. 
However, important determinants in successful gene inhibition by siRNAs are the 
identification of the most effective target sites and efficient delivery into cells. In this 
study the objectives included cloning, testing and specific delivery of siRNAs. Only 
some of these objectives were attained. 
Our first objective of this study was to design siRNAs against HER2, and clone them 
into an expression vectors. Sequencing data (section 3.2) verifies that cloning of the 
designed siRNAs (E1, E2 and E3) into vector was successful.  
Secondly, the cellular potencies of the designed siRNAs were investigated, in order 
to select the most effective agent. Some of the data obtained showed apparent HER2 
enhancing effects by the siRNAs, and will be addressed first. Data obtained from the 
second and third cytometry analysis showed increase in median fluorescence in 
transfected cells. This is more likely due to the presence of dead cells within the 
analysed samples. Dead cells are known to bind antibodies unspecifically, and indeed 
untransfected cells showed less unspecific staining with the irrelevant antibodies than 
transfected cells (Table 3). The reason why this has not affected the first and forth 
flow cytometry experiments might be a greater levels of transfection relative to dead 
cells, in these experiments. A more accurate estimation of unspecific staining due to 
dead cells could have been done using propidium iodide, which stains dead cells. The 
flow cytometry data from the fourth experiment showed negative results with E2 
(Table 2). However, this effect was not confirmed. Thus, it is more likely that the 
negative data obtained with E2 was due to some inaccuracy in execution of method. 
Northern blot also gave negative data (Table 5). Notably, total RNA prepared from 
untransfected cells exhibited a very strong signal that might have lead to inaccuracies 
accounting for the calculated negative effects (Fig.13, 5). Also, HER2 signal in cells 
transfected with only the vector was distorted (Fig.13, 4), so the low HER2/actin 
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mRNA ratio from these bands cannot be given any emphasis. On this basis we 
assume that there were no actual HER2 enhancing effects by the siRNAs. 
Concerning the positive silencing results from flow cytometry, they were mainly 
weak; around 15%. However, if measurements transfection levels (Fig.11b) are to be 
trusted, the silencing effects might actually be much higher. Notably, in the fourth 
flow cytometry experiment, differences in transfection levels between synthetic and 
vector delivered siRNAs (Fig.11 b and c), could explain the difference in activity for 
synthetic and vector delivered E3 (Table 2). Western blot gave a silencing effect of 
60% for E3 (Table 4), which could have been acceptable for further peptide delivery, 
if the result had been confirmed. Curiously, both the HER2 and actin protein bands 
were as doublets in the western blot (Fig.12). The reason of this is not known, but it 
is more likely due to a change of current when the proteins were on the border 
between the stacking gel and the running gel. As with amount of proteins loaded, 
doubling of the band should not influence intensity ratios.   
The main concern with the positive silencing results was the variation between the 
experiments (see Tables 1, 2 and 4). E1 showed no effect in western blot, while in the 
fourth flow cytometry experiment, it was apparently active. E2 was half as active as 
E3 according to western blot, while in the first cytometry experiment the two siRNAs 
had approximately similar activity. E3 showed no or little effect in the fourth 
cytometry experiment, while in the first experiment and in western blot it was the 
most active siRNA. Because of the variation of siRNA potency between the different 
experiments it was impossible to select siRNA for specific delivery using peptides. 
One can only speculate about reasons of the variations between the experiments. The 
weak silencing effects obtained by flow cutometry could have been caused by 
imprecision in the method used, hence the variation. Also, the positive western blot 
results could have been due to artefacts; conclusions are difficult to make when only 
one western experiment was performed. It is possible that none of the siRNAs were 
active, and that activities caused by siRNAs being optimised according to algorithm, 
were negated by target mRNA secondary structure: The steric accessibility of the 
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target location within the mRNA has been suggested as a major factor in siRNA 
activity, and its influence have been illustrated in several experiments (Kretschmer-
Kazemi Far et al. 2003; Vickers et al. 2003; Overhoff et al. 2005). Variation in 
activities could also have been caused by experimental conditions not being 
homologous. For example, if the cancer cells change morphology during cultivation, 
they could maybe influenced siRNA activity differently at different stages. In further 
experiments to disclose whether siRNAs are active or not, one should make effort to 
make the experimental conditions more homologous, maybe by using newly 
unfreezed cells only. Also, higher transfection levels should be established, maybe by 
using another cell line or transfection agent. High transfection levels are crucial for 
reliable results. 
There is no doubt that more work is required to properly investigate the activity of the 
designed siRNAs. What can be said from the overall data is that other factors than 
siRNA primary structure might have influenced activity, and that such factors are 
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